Financial Comparison: Vanda Pharmaceuticals (NASDAQ:VNDA) and Siga Technologies (NASDAQ:SIGA)

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Insider and Institutional Ownership

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Vanda Pharmaceuticals and Siga Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals -119.87% -62.70% -37.53%
Siga Technologies 1.31% 0.40% 0.35%

Valuation and Earnings

This table compares Vanda Pharmaceuticals and Siga Technologies”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vanda Pharmaceuticals $216.10 million 1.12 -$220.47 million ($4.62) -0.86
Siga Technologies $52.36 million 3.76 $23.28 million N/A N/A

Siga Technologies has lower revenue, but higher earnings than Vanda Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vanda Pharmaceuticals and Siga Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals 1 2 6 0 2.56
Siga Technologies 1 0 0 0 1.00

Vanda Pharmaceuticals currently has a consensus price target of $13.50, indicating a potential upside of 238.35%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Siga Technologies.

Risk & Volatility

Vanda Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003. Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome.

About Siga Technologies

(Get Free Report)

SIGA Technologies is a commercial-stage pharmaceutical company focused on developing and supplying treatments for serious infectious diseases. Its principal product is TPOXX (tecovirimat), an antiviral medicine approved in the United States to treat smallpox in adults and children. TPOXX is available in oral and intravenous formulations. SIGA supplies the medicine primarily to government agencies for emergency preparedness and response, including stockpiles intended to address potential smallpox outbreaks.

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.